Spago Nanomedical
0.206
SEK
+5.1 %
SPAGO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
+5.1%
+5.1%
+19.08%
-7.21%
-27.46%
-37%
-95.44%
-98.46%
-98.19%
Spago Nanomedical conducts research and development in cancer diagnostics. The company conducts various development projects based on its proprietary nanomaterials whose potential is found in making tumours visible, and enabling internal radiation therapy of cancer. The company was founded in 2007 and is based in Lund.
Read moreMarket cap
71.73M SEK
Turnover
8.76K SEK
Revenue
1.2M
EBIT %
-3,589.17 %
P/E
-
Dividend yield-%
-
Financial calendar
6/2
2025
Annual report '24
7/5
2025
Interim report Q1'25
20/8
2025
Interim report Q2'25
ShowingAll content types
Penser Access & Future by Carnegie: Spago Nanomedical: Andra dosgruppen redo för utvärdering av DMC
Andra patientgruppen framgångsrikt doserad i Spago Nanomedicals fas I/IIa-studie Tumorad-01
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools